Company InNexus Biotechnology, Inc.

Innexus Biotechnology Inc is a Canada-based development-stage company. The Company is a drug development company focused on commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. It is engaged in monetizing its technology for its own product development projects whether independently, through collaborations with strategic partners and/or through business development activities for the licensing and sale of its technologies and services. The Company focuses on developing and marketing DXL technology to the biotechnology and pharmaceutical community by launching and developing multiple product candidates. These candidates include potential therapeutic and diagnostic products.

Number of employees: 10